Autoimmune hepatitis develops when your immune system mistakenly attacks your own liver cells, causing inflammation that can progress to scarring and liver failure if untreated. No single cause explains every case. Instead, the disease appears to result from a combination of genetic vulnerability, environmental triggers, and immune system dysfunction that together push the body into attacking itself.
Genetic Susceptibility Sets the Stage
Certain inherited genes make some people far more likely to develop autoimmune hepatitis than others. The strongest links involve a group of genes that help your immune system distinguish your own cells from foreign invaders. Among white populations in Northern Europe and North America, two specific gene variants are the primary risk factors. One tends to appear in younger patients who develop more severe disease, while the other is more common in older patients with milder, more manageable illness. In Chinese populations, the same gene family is involved, but a different variant carries the risk, increasing the odds of developing the disease roughly threefold compared to people without it.
These genes don’t guarantee you’ll get autoimmune hepatitis. They simply make your immune system more prone to misidentifying liver proteins as threats. Most people with high-risk gene variants never develop the condition, which is why researchers believe an environmental trigger is usually needed to set the process in motion.
How the Immune System Turns on the Liver
The damage in autoimmune hepatitis follows a specific chain of events inside your body. It starts when immune cells encounter a protein on the surface of liver cells and mistakenly flag it as foreign. This triggers a cascade: one set of immune cells releases chemical signals that activate killer cells, which then directly attack and destroy liver tissue. At the same time, other immune cells arrive and release inflammatory compounds that amplify the damage.
In some cases, killer immune cells physically penetrate liver cells in a process called emperipolesis, which is associated with more severe inflammation and faster progression to scarring. The intensity of this immune attack is typically highest at the time of diagnosis and decreases once treatment begins, which is why early detection matters.
Molecular Mimicry: A Case of Mistaken Identity
One of the most compelling explanations for how autoimmune hepatitis starts involves molecular mimicry. Certain viruses and bacteria have protein structures that closely resemble proteins found naturally on liver cells. When your immune system builds a defense against the infection, those defenses can accidentally target the look-alike liver proteins too.
A liver enzyme called CYP2D6 is a key target in one form of the disease. Portions of this enzyme share amino acid sequences with hepatitis C virus, herpes simplex virus type 1, and certain human retroviruses. A bacterium in the Salmonella family also has a region that mimics this same enzyme. Similarly, the hepatitis B virus has structural similarities to the smooth muscle and nuclear proteins that the immune system targets in the more common form of the disease. Once the immune system learns to attack these shared structures, it can continue destroying liver cells long after the original infection has cleared.
Viral Infections as Triggers
Several specific infections have been linked to the onset of autoimmune hepatitis. A history of Epstein-Barr virus (the cause of mono), herpes viruses, parvovirus B19, or hepatitis A, B, or C all increase the risk. These infections don’t cause autoimmune hepatitis directly. Rather, they appear to activate the immune system in a way that, in genetically susceptible people, leads to a self-sustaining attack on the liver. The infection resolves, but the autoimmune process it triggered does not.
Medications That Can Trigger the Disease
Certain drugs can trigger a form of the condition known as drug-induced autoimmune hepatitis. Two medications carry the highest risk by a wide margin: nitrofurantoin, a common antibiotic used for urinary tract infections, and minocycline, a tetracycline antibiotic frequently prescribed for acne. Both have risk signals roughly 50 to 57 times higher than background rates in pharmacovigilance data. Doxycycline, another tetracycline, carries a smaller but still notable risk.
The timeline varies depending on the drug. Nitrofurantoin-associated cases typically emerge after a median of about 24 months of use, while minocycline cases appear after roughly 12 months. Cancer immunotherapy drugs, particularly checkpoint inhibitors used for melanoma and other cancers, can trigger liver autoimmunity much faster, sometimes within weeks. Immune-modulating drugs used for conditions like multiple sclerosis have also been linked to the disease, though they tend to take closer to a year to cause problems.
The Gut-Liver Connection
Your gut and liver are closely connected through shared blood supply, and growing evidence suggests that changes in gut bacteria play a role in autoimmune hepatitis. People with the condition have measurably lower levels of beneficial gut bacteria, including Bifidobacterium and Lactobacillus. The proteins that seal the gaps between intestinal lining cells are also reduced, meaning the gut barrier is leakier than normal.
This increased permeability allows bacterial products to escape the intestine and enter the bloodstream, where they travel directly to the liver. Blood levels of one such bacterial product (LPS) are elevated in autoimmune hepatitis patients. The theory is that this constant stream of microbial material reaching the liver keeps the immune system in a heightened state of alert, contributing to ongoing inflammation. Antibodies found in up to 92% of autoimmune hepatitis patients react to a protein that cross-reacts with a bacterial protein, further supporting the idea that gut bacteria are part of the puzzle.
Two Types, Different Targets
Autoimmune hepatitis comes in two forms, distinguished by which liver proteins the immune system attacks. Type 1 is the more common form and is marked by antibodies against smooth muscle and cell nuclei. Type 2 is rarer, more often affects children, and involves antibodies that target a specific liver enzyme (CYP2D6, the same enzyme involved in molecular mimicry with viruses). The distinction matters because type 2 tends to present more aggressively and at a younger age.
Who Gets It
Autoimmune hepatitis occurs across all races and age groups, but it disproportionately affects women. Incidence is higher in countries with very high development indices, in North America and Oceania compared to Asia, and at latitudes above 45 degrees north. Adults are diagnosed more often than children, though pediatric cases of type 2 can be particularly severe.
Between 20% and 40% of people with autoimmune hepatitis also have at least one other autoimmune condition. The most common is autoimmune thyroid disease, primarily Hashimoto’s thyroiditis, which affects 6% to 23% of patients. Type 1 diabetes co-occurs in 1% to 10% of cases, inflammatory bowel disease in 2% to 16%, and celiac disease in roughly 3% to 6%. This clustering of autoimmune conditions within the same person reinforces the idea that a shared genetic and immune vulnerability underlies all of them rather than each disease arising independently.
Epigenetic Changes: Genes Switched On or Off
Beyond the genes you’re born with, the way those genes are activated or silenced also matters. Environmental exposures can cause chemical modifications to your DNA that change how actively certain genes are read, without altering the genetic code itself. When these modifications loosen the DNA structure around immune-related genes, those genes become more active, potentially ramping up the inflammatory response. Small molecules called microRNAs can also interfere with the production of proteins that normally keep the immune system in check.
These epigenetic changes may help explain why autoimmune hepatitis can appear at any age and why genetically similar people can have very different outcomes. The specific patterns found in autoimmune hepatitis patients haven’t yet been fully connected to particular symptoms or disease severity, but they represent another layer of causation beyond simple genetic inheritance.